<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1683">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03084965</url>
  </required_header>
  <id_info>
    <org_study_id>D1690R00022</org_study_id>
    <nct_id>NCT03084965</nct_id>
  </id_info>
  <brief_title>Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan</brief_title>
  <official_title>Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in Taiwan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective Study of Patients With Type 2 Diabetes Mellitus on Dapagliflozin Therapy in
      Taiwan
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 10, 2017</start_date>
  <completion_date type="Anticipated">October 31, 2017</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>6 months</time_frame>
    <description>To assess the change from baseline (time to initiate dapagliflozin*) in HbA1c at 6 months</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>Type II Diabetes Mellitus</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Type 2 Diabetes Mellitus patients on Dapagliflozin Therapy in Taiwan
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Outpatient equal to or more than 20 years of age.

          2. T2DM patient initiated dapagliflozin after May 1st 2016 as a second line or third
             line oral anti-diabetic therapy, either as add-on or switching from one to another.
             Or initiating dapagliflozin as adjunctive therapy for T2DM subjects treated with
             insulin.

          3. Completed follow-up of at least 6 months regardless of continuation on dapagliflozin
             therapy.

          4. Will provide completed and signed written informed consents.

        Exclusion Criteria:

          1. Subjects with a history of SGLT2 inhibitor therapy other than dapagliflozin prior to
             Baseline.

          2. Subjects with Type 1 diabetes.

          3. Treatment with other investigational drugs concurrently during the retrospective data
             collection period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 15, 2017</lastchanged_date>
  <firstreceived_date>March 15, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
